Pharmaceutical Development


PBL works on a lucky day in Japan to make a life-saving product


Porton Biopharma limited (PBL) is working with Ohara Pharmaceutical Co., Ltd.  who has today submitted a New Drug Application  for Erwinase® in Japan.  The submission was specifically  timed because the 17th December is considered to be “a lucky day”  in the Japanese Rokuyo calendar and is known as Taian, 大安  . This is an auspicious good luck day for all concerned and is particularly good for wedding ceremonies and starting new business ventures, hence why it was chosen.

read more

PBL initiates its academic, professional and community engagement programme

students from Oxford Brookes University visit PBL

Developing links with a range of academic institutions, industry professionals and the local community is a key component of PBL’s engagement and marketing strategy.  This will enable us to keep up to date with latest research and innovative thinking, provide cross-linkages with academic and industry partners, and also develop potential career paths to enhance our workforce planning.

read more

PBL gains its first PhD

Dr Dave Gervais

We are pleased to announce that Dave Gervais, a Senior Scientist and Analytical Innovation Lead at PBL has been awarded the degree of Doctor of Philosophy from Oxford Brookes University.

read more

New director joins PBL

We are pleased to announce that Pat Mills, Commercial Director at the Department of Health has taken up a role as a Shareholder Director of PBL,

read more